Liquid Biopsy Market Research Report Information by Biomarker Types (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Extracellular Vesicles (EVS) and other Biomarker (Circulating RNA and Proteins)), Application (Cancer Therapeutic Application, Reproductive Health and Other Therapeutic Application), Sample (Blood Sample, Urine Sample and other), End User (Hospitals and Laboratories, Academic and Research Centers and other End Users) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) – Global Forecast to 2030
The liquid biopsy market is expected to reach USD 13.8 billion by 2030 at 12.4% CAGR during the forecast period 2022-2030. A liquid biopsy is a largely non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science, namely, human genome sequencing and rising sensitivity of detecting techniques and assays. The detection and follow-up of cancer have now taken centre stage in the healthcare system. The burden of cancer is growing, necessitating the development of innovative diagnostic and therapeutic approaches. The core cause of several cancers, including bone cancer, breast cancer, liver cancer, prostate cancer, and others, is currently of interest to researchers. Due to the rising incidence of uncommon cancers and the late detection of the diseases, new diagnostic and therapeutic approaches are also required. As the disease progresses throughout the body, late diagnosis decreases the likelihood of a successful treatment.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/710
One of the potential non-invasive techniques for cancer diagnosis is liquid biopsy. It entails taking a sample of tissue while it is still liquid. Compared to other diagnostic methods, it is a quick and painless way to diagnose cancer. As a result, both liquid and solid biopsies are crucial for the management of cancer and present the market with good growth prospects. The technology can also be used for prenatal testing, early diagnosis and assessment of drug resistance, and monitoring cardiac and neurologic disorders. It can now be used for monitoring organ transplants to close the gap between the demand for new technology and its need.
The worldwide liquid biopsy industry is being dominated by rising awareness of individualised cancer treatment. Demand for non-invasive testing is rising, cancer is becoming more common, and there has been a lot of study and development into the detection and treatment of cancer. The market is also fueled by a number of benefits of liquid biopsies, including their speedy analysis, ability to identify particular mutations, low cost, and need for less manpower. Additionally, growing consumer awareness of cancer diagnoses helps the industry expand. The major obstacle in cancer research, tumour heterogeneity, may, however, impede market expansion.
Liquid Biopsy Market Segmentation
The biomarker types, applications, samples, and end user segments have been created for the worldwide liquid biopsy market.
The global market is divided into extracellular vesicles (EVS), circulating tumour cells (CTCS), and circulating tumour DNA (CTDNA) based on the types of biomarkers they use.
The global market has been divided into categories for cancer, reproductive health, and other applications.
The global market is divided into blood sample, urine sample, forensic sample, and other sample based on the kind of sample.
The global market is divided into hospitals and laboratories, academic and research institutions, and other end users based on the end user. The commercial implementation of the method was also driven by advancements in detection technologies like digital PCR, enhanced cell capture technology, and multi-panel detection.
Liquid Biopsy Market Regional Analysis
According to region, the worldwide liquid biopsy market for healthcare is divided into North America, Europe, Asia-Pacific, and Middle East & Africa.
While Asia-Pacific is the market with the quickest growth, North America held the highest market share. The US and numerous European nations created the liquid biopsy technique, which is seen in the dominance of these two regions in their respective market shares. The market in Europe is anticipated to expand at the fastest CAGR. Between 2001 and 2010, the amount of venture financing available to life sciences startups more than doubled.
Nearly 20% of all investments made in Europe are made in the UK, and nearly 20% of that country’s venture capital was allocated to the healthcare industry.
Asia-Pacific is the region with the quickest market growth and is anticipated to expand at an exponentially high CAGR during the anticipated period. It is anticipated that the Middle East and Africa would have a small market but steady growth. Globally, 8.2 million cancer-related fatalities and 14 million new cases were reported in 2012; within the next 20 years, this number is expected to rise to 22 million. Nearly two thirds of the cases and seventy percent of the fatalities occur in Africa, the Asia-Pacific region, and Central and South America.
Browse In-depth Market Research Report (171 Pages) on Liquid Biopsy: https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710
The major players in the global liquid biopsy market are Guardant Health, Inc. (US), Trovagene, Inc. (California), RainDance Technologies, Inc. (US), Agena Bioscience Inc. (California), Admera Health (US), Biocept, Inc. KGaA (US), Circulogene Theranostics (Alabama), Inivata Ltd (UK), SAGA Diagnostics AB (Sweden), and Exosome Diagnostics (Massachusetts).
Browse Related Reports at
Biopsy Devices Market Share, Growth And Trends Analysis By Product Type (Biopsy Guns, Biopsy Guidance System, Biopsy Needles, Forceps And Others), By Application (Surgical Biopsy, Skin Biopsy, Needle Biopsy, Bone Marrow Biopsy, Cancer Diagnosis And Others), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes And Others) – Forecast Till 2030
Bone Biopsy Market Information by Type (Needle Biopsy, Open Biopsy), by Guided (MRI-Guided and CT-Guided), by End User (Hospitals & Clinics, Surgical Centers, and Others), and by Region (North America, Europe, Asia-Pacific, and the Rest of the World)—Forecast till 2030
Breast Biopsy Market By Product (Biopsy Needles, Biopsy Tables), Technique Type (Fine Needle Aspiration Biopsy, Core Needle Biopsy), Guidance Technology (Ultrasound-Guided, CT-Guided Biopsy), End-Users (Hospitals, Labs)- Forecast Till 2027
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)